Genistein in autoimmune diseases: from experimental evidence to emerging clinical data

By
Stefan Tukaj
July 6, 2026
0 min

Frontiers In Immunology

Overview

Genistein, a soy-derived isoflavone, has been studied for its immunomodulatory effects in autoimmune diseases. Preclinical studies indicate its potential to attenuate inflammatory responses and modulate autoimmune pathways, although clinical evidence in humans is limited.

Background

Autoimmune diseases are chronic inflammatory disorders characterized by the loss of immune tolerance. Current treatment options, including immunosuppressive and biologic therapies, often have variable efficacy and associated adverse effects. This has led to interest in complementary strategies, such as the use of bioactive compounds like genistein.

Data Highlights

No specific numerical or trial data is provided in the source material.

Key Findings

Genistein has anti-inflammatory, antioxidant, and immunoregulatory properties.
It functions as a tyrosine kinase inhibitor and modulates signaling pathways involved in immune regulation.
Preclinical evidence supports its efficacy in models of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases.
Genistein administration has been linked to reduced disease severity and modulation of autoimmune pathways in experimental models.
Preliminary studies suggest immunomodulatory effects in humans, though clinical evidence is limited.

Clinical Implications

Further investigation is needed to understand the role of genistein in autoimmune disorders.

Conclusion

Preclinical evidence supports the immunomodulatory role of genistein in autoimmune diseases. Further clinical studies are needed to establish its efficacy and safety in human populations.